$107.18
2.08% today
NYSE, May 15, 04:46 pm CET
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Novartis ADR Stock price

$104.99
-4.47 4.08% 1M
+1.59 1.54% 6M
+7.68 7.89% YTD
+1.68 1.63% 1Y
+21.86 26.30% 3Y
+25.44 31.98% 5Y
+6.63 6.74% 10Y
NYSE, Closing price Wed, May 14 2025
-1.84 1.72%
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Key metrics

Market capitalization $199.23b
Enterprise Value $223.38b
P/E (TTM) P/E ratio 16.32
EV/FCF (TTM) EV/FCF 12.69
EV/Sales (TTM) EV/Sales 4.32
P/S ratio (TTM) P/S ratio 3.85
P/B ratio (TTM) P/B ratio 5.36
Dividend yield 3.80%
Last dividend (FY25) $3.99
Revenue growth (TTM) Revenue growth 6.30%
Revenue (TTM) Revenue $51.72b
EBIT (operating result TTM) EBIT $16.36b
Free Cash Flow (TTM) Free Cash Flow $17.61b
Cash position $7.20b
EPS (TTM) EPS $6.39
P/E forward 15.40
P/S forward 3.67
EV/Sales forward 4.12
Short interest 0.23%
Show more

Is Novartis ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Novartis ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Novartis ADR forecast:

4x Buy
16%
15x Hold
60%
6x Sell
24%

Analyst Opinions

25 Analysts have issued a Novartis ADR forecast:

Buy
16%
Hold
60%
Sell
24%

Financial data from Novartis ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
51,721 51,721
6% 6%
100%
- Direct Costs 13,210 13,210
3% 3%
26%
38,511 38,511
10% 10%
74%
- Selling and Administrative Expenses 6,879 6,879
32% 32%
13%
- Research and Development Expense 9,368 9,368
8% 8%
18%
22,264 22,264
5% 5%
43%
- Depreciation and Amortization 5,905 5,905
25% 25%
11%
EBIT (Operating Income) EBIT 16,359 16,359
23% 23%
32%
Net Profit 12,859 12,859
16% 16%
25%

In millions USD.

Don't miss a Thing! We will send you all news about Novartis ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis ADR Stock News

Neutral
GlobeNewsWire
about 2 hours ago
Basel, May 15, 2025 – Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress.
Neutral
Seeking Alpha
3 days ago
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have ri...
Positive
Reuters
3 days ago
Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told Reuters in an interview.
More Novartis ADR News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 75,883
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today